ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.
about
The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemiaWhy Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Reduced apolipoprotein glycosylation in patients with the metabolic syndromeApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacityComplexities of plasma apolipoprotein C-III metabolismIncreased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma.Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS)The role of triglycerides in atherosclerosis.Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart diseaseAn Efficient Single Phase Method for the Extraction of Plasma Lipids.The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma TriglyceridesLevels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients.The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosisArterial retention of remnant lipoproteins ex vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp ratDisialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetesShotgun Lipidomics by Sequential Precursor Ion Fragmentation on a Hybrid Quadrupole Time-of-Flight Mass SpectrometerEpanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.Molecular biology of atherosclerosis.Sialic acids: biomarkers in endocrinal cancers.Apolipoprotein CIII induces monocyte chemoattractant protein-1 and interleukin 6 expression via Toll-like receptor 2 pathway in mouse adipocytes.Lipidomics: a tool for studies of atherosclerosis.Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes.Neither polyphenol-rich red wine nor fenofibrate affects the onset of type-1 diabetes mellitus in the BB rat
P2860
Q26864682-05F1FDB8-2C71-453A-8970-21BA438B24CDQ28077776-7D315458-02C6-4EEC-9458-CD4323FF712AQ28541818-BE0A0294-D8C6-48F3-996E-5CB4ED8412D5Q33725659-D1E85629-CDF3-41F1-9BDD-578D0608AA8FQ34172178-45559270-6446-42B4-A1F7-DC14C27BDD2CQ34489747-ECF07FAE-D2D6-4D39-BE00-1365CB8D0DB6Q34551430-FEA02B86-8CF1-4174-A9F9-B4FED0472854Q34608381-D7383727-94C1-4284-BA36-16D510C90527Q35602424-430F72A4-57B4-45B0-9120-6A68EF781833Q35628166-4F7DF3DC-F2A6-4A08-A348-F0713CD641B2Q35829914-D66CC344-8749-457A-8A84-4A1B48877E4AQ35860314-48B29CE7-3E0F-489A-BB1A-87672893EB00Q35886333-45A2B687-BD58-48E8-8390-A403B4B1D533Q36192960-CD76F035-D23A-4F52-B3A3-2A7F29ABBDCEQ36522670-8094605F-A950-433E-B32B-A0951A18042EQ36843331-8888F1BA-1B3E-44AE-AA08-2FC2289DC8CEQ37512573-9876D1D8-D59E-4870-92CA-C95D9F513433Q38086841-49A0830A-C92A-4863-95AB-FEE30C05AD7DQ38125279-2FCF09B8-5176-4E4B-BEF4-71E30173B03CQ38380548-BDE08785-0CBD-460C-90A3-C21D90073E2DQ38860543-D2321C52-AC1A-4C0D-BBD6-21A3E319BAF5Q40815709-9CB25CBA-A3C2-431C-B5E4-FA7D2F2DA75DQ41293822-81105557-E0C4-4F49-AE59-28EE5B879FB4Q57494789-69350765-051A-4DA1-9A4C-C783337F09B1
P2860
ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ApoCIII-enriched LDL in type 2 ...... increased binding to biglycan.
@en
ApoCIII-enriched LDL in type 2 ...... increased binding to biglycan.
@nl
type
label
ApoCIII-enriched LDL in type 2 ...... increased binding to biglycan.
@en
ApoCIII-enriched LDL in type 2 ...... increased binding to biglycan.
@nl
prefLabel
ApoCIII-enriched LDL in type 2 ...... increased binding to biglycan.
@en
ApoCIII-enriched LDL in type 2 ...... increased binding to biglycan.
@nl
P2093
P2860
P50
P356
P1433
P1476
ApoCIII-enriched LDL in type 2 ...... increased binding to biglycan.
@en
P2093
Anne Hiukka
Camilla Pettersson
Eeva S Leinonen
Kim Ekroos
Lillemor Mattsson Hultén
Malin Levin
Marja-Riitta Taskinen
Martin Adiels
Susanne Teneberg
P2860
P304
P356
10.2337/DB09-0206
P407
P577
2009-06-05T00:00:00Z